Verrica Pharmaceuticals Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for VRCA, updated each market day.
VRCA AI Sentiment
AI sees no strong directional signal for Verrica Pharmaceuticals Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Verrica Pharmaceuticals Inc. Common Stock
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Sector
Exchange
Market Cap
$100,152,322
Cap Tier
Employees
76
Headquarters
WEST CHESTER, PA
Listed Since
June 15, 2018
Website
VRCA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VRCA Volatility
Verrica Pharmaceuticals Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
